Anti-HBc quantitative detection method, and its use in the monitoring and management as well as the prediction of the therapeutic effect of disease progression of chronic hepatitis B patients
Disclosed in the present invention is a method for quantitative detection of antibodies to hepatitis B core protein (anti-HBc) and its use in monitoring and managing disease progression and predicting therapeutic effects in patients with chronic hepatitis B. Anti-HBc is detected quantitatively, so that disease progression in chronic hepatitis B patients is monitored and managed, during anti-hepatitis B virus (HBV) treatment (especially during interferon-based treatment, and nucleoside analogs or The therapeutic effect on chronic hepatitis B patients (under treatment with anti-HBV drugs based on nucleotide analogues) is effectively predicted, thereby guiding the patient to rationally select the drug.B型肝炎コアタンパク質に対する抗体(抗HBc)の定量的検出方法、並びに慢性B型肝炎患者の疾患進行の監視及び管理並びに治療効果の予測におけるその使用が本発明において開示される。抗HBcが定量的に検出され、その結果、慢性B型肝炎患者の疾患進行が監視及び管理され、抗B型肝炎ウイルス(HBV)治療中(特に、インターフェロンに基づく治療中、及びヌクレオシド類似体又はヌクレオチド類似体に基づく抗HBV薬による治療中)である慢性B型肝炎患者に対する治療効果が効果的に予測され、それによって、薬を合理的に選択するように患者を導く。